Cue Biopharma
Open
$14.78
Prev. Close
$14.78
High
$14.82
Low
$14.76
Market Snapshot
$34.12M
-1.3
-0.72
$9.29M
29
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
emptyResult
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Recently from Cashu
Cue Biopharma Advances Immunotherapy with Targeted T Cell Modulation for Personalized Medicine
Cue Biopharma Innovates in Immunotherapy Cue Biopharma is at the forefront of developing cutting-edge immunotherapeutic approaches, focusing on the modulation of disease-specific T cells directly with…
Please provide the text you'd like me to summarize.
Sure, please provide the text you would like me to summarize into a 300-word paragraph.
Cue Biopharma's Innovative Clinical Trials Transforming Immunotherapy for Cancer and Autoimmune Disorders
Cue Biopharma Advances in Immunotherapy with Innovative Clinical Trials Cue Biopharma, a pioneering company in the biopharmaceutical sector, is making significant strides in the field of immunotherapy…
Please provide the content you would like summarized, and I'll help you with a title.
Sure! Please provide the content you would like summarized, and I will create an article based on the specified structure.